Novavax COVID shot may attract the vaccine-hesitant

Company hopes new drug which uses the same technology in shingles, hepatitis B, and influenza vaccines, will interest those who have hesitated to make use of mRNA vaccines.

A COVID-19 vaccine that is different from vaccines that use messenger RNA technology is set to receive approval from the U.S. Food and Drug Administration.

Advisers to the FDA on Tuesday voted to recommend that the agency authorize Novavax’s COVID vaccine for use in adults, Reuters reported. The drugmaker hopes the vaccine will attract some Americans who have been skeptical of COVID vaccines in general.